According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...